Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Correction: Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.

Autor: Zhang S, Yan C, Millar DG, Yang Q, Heather JM, Langenbucher A, Morton LT, Sepulveda S, Alpert E, Whelton LR, Zarrella DT, Guo M, Minogue E, Lawrence MS, Rueda BR, Spriggs DR, Lu W, Langenau DM, Cobbold M

Publikováno v: Cancer research [Cancer Res] 2024 May 02; Vol. 84 (9), pp. 1534.

Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction.

Autor: O'Brien H; Achilles Therapeutics Ltd, London, UK., Salm M; Achilles Therapeutics Ltd, London, UK. m.salm@achillestx.com., Morton LT; Achilles Therapeutics Ltd, London, UK., Szukszto M; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK., O'Farrell F; Achilles Therapeutics Ltd, London, UK., Boulton C; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK., Becker PD; Achilles Therapeutics Ltd, London, UK., Samuels Y; Weizmann Institute of Science, Rehovot, Israel., Swanton C; The Francis Crick Institute, London, UK., Mansour MR; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK., Reker Hadrup S; Technical University of Denmark, Lyngby, Denmark. sirha@dtu.dk., Quezada SA; Achilles Therapeutics Ltd, London, UK. s.quezada@ucl.ac.uk.; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK. s.quezada@ucl.ac.uk.

Publikováno v: Nature cancer [Nat Cancer] 2024 Apr; Vol. 5 (4), pp. 692.

Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential.

Autor: van Amerongen RA; Department of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Morton LT; Department of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Chaudhari UG; LUMC hiPSC Hotel, Department of Anatomy and Embryology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Remst DFG; Department of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Hagedoorn RS; Department of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., van den Berg CW; Department of Internal Medicine-Nephrology and Einthoven Laboratory of Vascular and Regenerative Medicine, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Freund C; LUMC hiPSC Hotel, Department of Anatomy and Embryology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Falkenburg JHF; Department of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands., Heemskerk MHM; Department of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands.

Publikováno v: Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2023 Jan 20; Vol. 28, pp. 249-261. Date of Electronic Publication: 2023 Jan 20 (Print Publication: 2023).

Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.

Autor: Zhang S; Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases & Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts., Yan C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.; Molecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, Massachusetts., Millar DG; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts., Yang Q; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.; Molecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, Massachusetts., Heather JM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts., Langenbucher A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts., Morton LT; University of Birmingham, Birmingham, United Kingdom., Sepulveda S; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts., Alpert E; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.; Molecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, Massachusetts., Whelton LR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.; Molecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, Massachusetts., Zarrella DT; Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, Massachusetts.; Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, Massachusetts., Guo M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts., Minogue E; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts., Lawrence MS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts., Rueda BR; Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, Massachusetts.; Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, Massachusetts., Spriggs DR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts., Lu W; Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases & Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China., Langenau DM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.; Molecular Pathology Unit, Massachusetts General Hospital Research Institute, Charlestown, Massachusetts., Cobbold M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.; AstraZeneca, Gaithersburg, Maryland.

Publikováno v: Cancer research [Cancer Res] 2022 Mar 01; Vol. 82 (5), pp. 773-784.